NRx Pharmaceuticals (NASDAQ:NRXP) Earns Buy Rating from D. Boral Capital

NRx Pharmaceuticals (NASDAQ:NRXP)‘s stock had its “buy” rating reiterated by stock analysts at D. Boral Capital in a note issued to investors on Monday,Benzinga reports. They presently have a $31.00 price objective on the stock.

Other equities analysts have also issued reports about the stock. Ascendiant Capital Markets lifted their target price on shares of NRx Pharmaceuticals from $44.00 to $45.00 and gave the company a “buy” rating in a report on Monday, December 2nd. HC Wainwright reaffirmed a “buy” rating and issued a $19.00 price objective on shares of NRx Pharmaceuticals in a report on Thursday, March 20th.

NRx Pharmaceuticals Stock Performance

Shares of NRXP opened at $2.03 on Monday. The business’s 50-day moving average is $2.57 and its two-hundred day moving average is $2.05. The company has a market capitalization of $34.34 million, a P/E ratio of -0.95 and a beta of 1.22. NRx Pharmaceuticals has a fifty-two week low of $1.10 and a fifty-two week high of $6.01.

NRx Pharmaceuticals (NASDAQ:NRXP) last issued its earnings results on Friday, March 14th. The company reported ($0.30) EPS for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.10). Analysts forecast that NRx Pharmaceuticals will post -1.75 EPS for the current year.

Institutional Investors Weigh In On NRx Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the stock. AdvisorShares Investments LLC lifted its holdings in NRx Pharmaceuticals by 138.5% during the fourth quarter. AdvisorShares Investments LLC now owns 310,314 shares of the company’s stock valued at $683,000 after purchasing an additional 180,229 shares in the last quarter. Anson Funds Management LP purchased a new position in NRx Pharmaceuticals in the 3rd quarter valued at about $241,000. Millennium Management LLC acquired a new stake in NRx Pharmaceuticals in the 4th quarter worth about $61,000. Squarepoint Ops LLC acquired a new stake in NRx Pharmaceuticals in the 4th quarter worth about $56,000. Finally, Townsquare Capital LLC purchased a new stake in NRx Pharmaceuticals during the 3rd quarter worth approximately $25,000. Institutional investors and hedge funds own 4.27% of the company’s stock.

NRx Pharmaceuticals Company Profile

NRx Pharmaceuticals, Inc, a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior.